Malignant Central Nervous System Neoplasm

Malignant Central Nervous System Neoplasm — Trials · CancerIndex

Clinical trials

Registered studies

2,864 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 822
Recruiting: 449
Ph III recruiting: 27
Growth YoY: +21.1%
Industry share: 16%
Top sponsor: National Cancer Institute (NCI)
Termination share: 34.9%
Trials / 1,000 deaths: 45.2 USA 2023 cdc-uscs

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (419)

clinicaltrialsPublishedShowing 101–140 of 140 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT00295815	Enzastaurin Versus Lomustine in Glioblastoma	completed	Phase 3	397	Eli Lilly and CompanyINDUSTRY	14	Sep 12, 2019	clinicaltrials
NCT01014767	Intercontinental Multidisciplinary Registry and Treatment Optimization Study for Choroid Plexus Tumors	terminated	Phase 3	27	Tufts Medical CenterOTHER	4	Aug 20, 2019	clinicaltrials
NCT00884741